ClinicalTrials.Veeva

Menu

Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status

Terminated

Conditions

Sarcoidosis
Inflammation
Lung Cancer
Lung Disease

Study type

Observational

Funder types

Other

Identifiers

NCT02168036
1104011629

Details and patient eligibility

About

The purpose of this protocol is to obtain biologic materials from the mediastinal lymph nodes from patients with lung disease and mediastinal lymph node involvement in order to: (1) develop a better understanding of the cause and development of lung disorders involving the mediastinal lymph nodes; (2) identify biologic parameters that help diagnose and predict the behavior of human lung diseases; and (3) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs.

Full description

This study will use bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as part of their diagnostic work up as recommended by the treating physician. The procedure will be performed as standard of care, either under general anesthesia in the operating room or in the bronchoscopy suite under moderate sedation and analgesia. Bronchoscopy with EBUS-TBNA is normally an ambulatory procedure. During the procedure, biopsy needle will be passed through the tube and a small sample will be taken for both diagnostic and research purposes. Samples collected for diagnostic purposes will be sent to the Department of Pathology. Additional biopsy samples will be collected for research purposes. The subject is observed after the bronchoscopy, including vital signs and level of consciousness, until they are back to baseline. All subjects will be discharged with an escort as per Hospital policy. An overnight stay would be required for ambulatory individuals only if the individual is not, in the judgment of the treating attending physician, safe to be discharged as is standard practice.

Enrollment

56 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must provide informed consent

  • Males and females, age 18 years and older

  • Lung disease proven by at least one of the following:

    1. symptoms consistent with pulmonary disease
    2. chest X-ray and chest CT and/or PET CT scan consistent with lung disease and mediastinal lymph node involvement
    3. lung biopsy consistent with lung disease known to involve mediastinal lymph nodes
    4. patients with diseases of organs with known association to lung disease and mediastinal lymph node involvement.
  • Undergoing fiberoptic bronchoscopy with EBUS-TBNA as dictated by their standard clinical care

Exclusion criteria

  • Patient refuses consent.
  • Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, or any local anesthetic will not be included in the study
  • Individuals who cannot tolerate general anesthesia or moderate sedation and analgesia

Trial design

56 participants in 1 patient group

Patients with lung disease
Description:
General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems